BOPA Introduction to Oncology Course

DATE FOR YOUR DIARY - Registration for this meeting is now open.

Following the successes of previous courses, BOPA is pleased to announce

BOPA Introduction to Oncology Course

Wednesday 25 – Friday 27 April 2012
Holiday Inn, Walsgrave, Coventry

Educational webinar

BOPA is delighted to announce its first ever educational webinar, to be hosted by Fiona Maclean (MRPharmS, MSc, IPres), Lead Clinical Pharmacist, Regional Services Directorate - Cancer South & Clyde, and Neurosciences). The topic of the Webinar is Lung Cancer and will build on the eLearning module available to BOPA members on the eLearning website.

Interactive Meeting Report of Annual Symposia 2011

BOPA is delighted to announce the release of the Interactive Meeting Report of its Annual Symposia 2011 in Glasgow. This contains reports from the key sessions and links to videos, slides from the event and much more. To access the report please click here

National bowel cancer campaign: Pharmacy factsheet

“A national campaign will launch in England on January 30 to raise awareness of the symptoms of bowel cancer, and encourage people with symptoms to visit their GP. The Department, with Cancer Research UK, has developed a Pharmacy factsheet in advance of the launch of the campaign, to support pharmacists and their teams with information about bowel cancer and how they can prepare for the possible increase in the number of customers asking questions about bowel cancer or presenting with the relevant symptoms or purchasing relevant over-the-counter medicines.  This factsheet has been written with the input of pharmacy representatives.  

 

Income Tax Relief in respect of annual membership subscriptions

Income Tax Relief in respect of annual membership subscriptions

HM Revenue and Customs have now granted approval for BOPA annual subscriptions to qualify for tax relief.

This is effective from 6th April 2011.  Members should contact their local tax office in writing.

Reference number RH/T1644/33/2011/JEM must be quoted on all applications.

MHRA Drug Alerts

Title: Class 2 Drug Alert (Action within 48 hours): Janssen-Cilag Ltd - Velcade 3.5 mg powder for solution for injection - EL (11)A/29

Title: Class 2 Drug Alert (Action within 48 hours): Pierre Fabre Médicament - Busilvex 6mg/ml concentrate for solution for infusion - EL (11)A/30